SKI-606 (Bosutinib): Mechanism of Action

SKI-606 (Bosutinib) MOA:Targeting BCR-Abl/Tyrosine Kinase Pathway for Chronic Myeloid Leukemia

🎯 check SKI-606 (Bosutinib) product page

Bosutinib is a potent, ATP-competitive Src/Abl kinase inhibitor. It affects BCR-ABL and Src signaling pathways by competing with ATP to inhibit kinase phosphorylation, effectively suppressing cancer cell proliferation and inducing apoptosis.

Primary Applications and Mechanism of Action